56 completed, 29 recruiting, 14 unknown, 13 terminated. 126 Phase 3, 27 Phase 2.
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera AG-236, Placebo - Polycythemia Vera | Phase 2 / Phase 3 | Not yet recruiting | Agios Pharmaceuticals, Inc. | 245 | 2026-11-01 | 2026-10-13 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-10-29 | 2026-11-13 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies Luspatercept, Epoetin - Luspatercept, Epoetin | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 90 | 2026-06-15 | 2026-06-09 |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Recruiting | Quetzal Therapeutics | 150 | 2026-06-08 | 2026-10-30 |
| Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies Acalabrutinib maleate, bortezomib, HLA-matched or crossmatched irradiated platelets - Hematological Malignancies, Platelet Transfusion Refractoriness (PTR) | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 42 | 2026-06-01 | 2026-06-09 |
| INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) Sapablursen, Placebo - Polycythemia Vera | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 250 | 2026-05-25 | 2026-10-29 |
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT Methotrexate, Anti-CD25 Monoclonal Antibody - Graft Versus Host Disease, Hematologic Neoplasms | Phase 3 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 186 | 2026-05-01 | 2026-07-08 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT Maribavir - Hematologic Malignancy | Phase 3 | Recruiting | Ruijin Hospital | 218 | 2026-02-28 | 2026-04-06 |
| Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy Educational Intervention, Health Telemonitoring, Questionnaire Administration - Hematologic Malignancies | Phase 3 | Recruiting | City of Hope Medical Center | 380 | 2026-01-14 | 2026-08-28 |
| Influenza Vaccination Strategy for Patients With Hematologic Malignancy High-dose trivalent inactivated influenza vaccine (HD-IIV3), MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4), Standard-dose trivalent inactivated influenza vaccine (SD-IIV3) - Hematologic Neoplasms, Influenza | Phase 3 | Recruiting | Asan Medical Center | 120 | 2025-12-04 | 2026-09-01 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML Ziftomenib, Placebo, Venetoclax - Acute Myeloid Leukemia (AML) | Phase 3 | Recruiting | Kura Oncology, Inc. | 1300 | 2025-09-26 | 2026-11-12 |
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies GLPG CAR T-cell therapy - Hematological Malignancies | Phase 3 | Recruiting | Lakefront Biotherapeutics NV | 546 | 2024-09-09 | 2026-07-13 |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Pelabresib, Ruxolitinib - Hematologic Malignancy, Solid Tumor | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-08-13 | 2026-11-12 |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients Biospecimen Collection, Letermovir - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 3 | Recruiting | Children's Oncology Group | 105 | 2024-07-11 | 2026-10-06 |
| CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT Letermovir - Hematologic Malignancy | Phase 3 | Active not recruiting | Ruijin Hospital | 250 | 2024-07-01 | 2025-12-15 |
Showing 20 of 126. Sign in to see all of them.
Polycythemia Vera (35) · Multiple Myeloma (20) · Myeloproliferative Disorders (20) · Leukemia, Myeloid, Acute (18) · Neoplasms (18) · Thrombocythemia, Essential (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Primary Myelofibrosis (17) · Myelodysplastic Syndromes (16) · Leukemia, Lymphocytic, Chronic, B-Cell (15) · Lymphoma, Large B-Cell, Diffuse (15) · Hodgkin Disease (14) · Leukemia (14) · Lymphoma (14)
Hemic and Lymphatic Diseases (126) · Neoplasms by Site (120) · Hematologic Diseases (117) · Neoplasms (108) · Bone Marrow Diseases (43) · Immune System Diseases (36) · Bone Marrow Neoplasms (35) · Pathological Conditions, Signs and Symptoms (34) · Neoplasms by Histologic Type (33) · Immunoproliferative Disorders (32) · Lymphatic Diseases (29) · Pathologic Processes (29) · Hemorrhagic Disorders (27) · Cardiovascular Diseases (25)
Hydroxyurea (8) · Cyclophosphamide (7) · ruxolitinib (7) · Early Intervention, Educational (4) · Olanzapine (4) · Standard of Care (4) · Antilymphocyte Serum (3) · Aspirin (3) · Practice Guidelines as Topic (3) · Stem Cell Transplantation (3) · Tranexamic Acid (3) · Voriconazole (3) · Whole-Body Irradiation (3) · fludarabine phosphate (3) · peginterferon alfa-2b (3)
Cancer Research UK (7) · Novartis Pharmaceuticals (6) · Fred Hutchinson Cancer Center (5) · Alliance for Clinical Trials in Oncology (4) · M.D. Anderson Cancer Center (4) · Merck Sharp & Dohme LLC (4) · Nanfang Hospital, Southern Medical University (4) · AOP Orphan Pharmaceuticals AG (3) · Assistance Publique - Hôpitaux de Paris (3) · Children's Oncology Group (3) · Memorial Sloan Kettering Cancer Center (3) · Ottawa Hospital Research Institute (3) · Amgen (2) · CTI BioPharma (2) · Gamida Cell ltd (2)
United States (64) · France (31) · United Kingdom (29) · Italy (27) · Germany (25) · Canada (24) · Spain (22) · Belgium (21) · Hungary (18) · China (16) · Netherlands (16) · Australia (15) · Czechia (15) · Austria (13) · Poland (13)
Matthew Krebs, Dr (6) · Heinz Gisslinger, MD (3) · Qifa Liu (3) · Brenda Sandmaier (2) · Charles L Loprinzi (2) · Mitchell Horwitz, MD (2) · Agha Mounzer, MD (1) · Alan Tinmouth, MD (1) · Alan Tinmouth, MD MSc (1) · Alberto Bosi, MD (1) · Amber B Clemmons, PharmD (1) · Aminah Jatoi, MD (1)
PMID 29396713, PMID 32499241, PMID 33275766, PMID 41890273, PMID 15459300, PMID 17397698, PMID 20424252, PMID 20525993, PMID 21467546, PMID 21856226, PMID 22207416, PMID 22480131, PMID 22814329, PMID 23109697, PMID 23216616, PMID 23502220, PMID 24335106, PMID 24472814, PMID 24532039, PMID 25478136, PMID 25629741, PMID 25961767, PMID 26181658, PMID 26700120, PMID 26700123, PMID 27020837, PMID 27102499, PMID 27410922, PMID 27798034, PMID 27916398, PMID 28096091, PMID 28193568, PMID 29253068, PMID 29477778, PMID 29895954, PMID 29906570, PMID 30287855, PMID 31248843, PMID 31399378, PMID 31515250, PMID 31606897, PMID 31615553, PMID 31756535, PMID 31958417, PMID 31982039, PMID 32083994, PMID 32665955, PMID 32781287, PMID 33136159, PMID 33811823
2023 (4), 2014 (3), 2025 (3), UG1CA189955 (3), 2016 (2), P30CA015704 (2), 2008 (1), 2017 (1), P01CA018029 (1), P01CA078902 (1), P01CA108671 (1), P30CA015083 (1), P30CA068485 (1), R01CA126971 (1), R01CA127655 (1)